Delivery Order SPE2DB22D3501-SPE2DB26FTK54
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Eucrisa 2% Ointment in 60-gram quantities, with a ceiling value of $1,688.16. This firm fixed-price delivery order, which is not set-aside and was competitively awarded, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 18, 2025. The delivery order is issued under AmerisourceBergen's...
- The federal contract award is for the delivery of Eucrisa 2% ointment, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $1,384.68 firm fixed-price delivery order was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. This award is a part of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and expiring in November 2026. The IDC serves as a primary...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The $1,808.20 firm-fixed-price contract is for the supply of EUCRISA 2% ointment, a pharmaceutical product, with an ultimate completion date of August 17, 2023. Amerisourcebergen Drug Corp's Corporate Office division is the prime contractor for this award. The company is a major supplier of pharmaceutical products and medical supplies to...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,913.99, is for the delivery of EUCRISA 2% Ointment 60GM, a pharmaceutical product. The contract has an ultimate completion date of September 20, 2023. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,152.59 firm fixed-price delivery order is for the supply of EUCRISA 2% ointment, a topical medication, with a performance period ending on May 20, 2025. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,372.25, is for the delivery of EUCRISA 2% Ointment 60GM, a pharmaceutical product. The contract is a firm fixed-price delivery order that does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is the prime contractor, and...
- The Defense Logistics Agency Troop Support Medical awarded a $904.12 firm fixed price delivery order to Amerisourcebergen Drug Corp Corporate Office Division for 60 grams of EUCRISA 2% ointment. The place of performance is Conshohocken, Pennsylvania. The period of performance is September 25-26, 2023. This delivery order was issued against an indefinite-delivery/indefinite-quantity contract vehicle to supply pharmaceutical products in support of the Defense Logistics Agency's medical supply...
- Amerisourcebergen Drug Corporation, a division of Amerisourcebergen Corporation, has been awarded a firm fixed price delivery order valued at $4,623.26 by the Defense Logistics Agency Troop Support Medical (DLA) to provide 60 grams of EUCRISA 2% ointment. The place of performance will be Amerisourcebergen's facility located in Conshohocken, Pennsylvania. The period of performance is August 21-22, 2023. No set aside designation or subcontractors are indicated. DLA manages the global supply...
- The Defense Logistics Agency awarded a firm fixed price delivery order valued at approximately $1,236 to Amerisourcebergen Drug Corporation. The order is for 60 grams of EUCRISA 2% ointment to be delivered to a facility in Conshohocken, Pennsylvania by July 11, 2023. Amerisourcebergen Drug Corporation will perform as the prime contractor, with its parent company listed as Amerisourcebergen Corporation. No subcontractors or set aside designations were indicated. The Defense Logistics Agency...
- This federal contract award from the Defense Logistics Agency (DLA) was granted to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies to the U.S. government. The $1,343.33 delivery order contract is for the provision of EUCRISA 2% ointment 100GM, a prescription medication. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued up to $999,999,999.00 through December 2025,...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB26FTK54Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,657.85 to AmerisourceBergen Drug Corp for Eucrisa 2% Ointment (60 grams) on November 5, 2025, with completion targeted for November 6, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor in the federal medical supply chain and holds a significant Indefinite Delivery Contract with DLA Troop Support Medical valued at $999,999,999.00 through December 2026. This delivery order is issued under AmerisourceBergen's broader IDC with the Defense Logistics Agency, which provides pharmaceutical and medical supply support to military healthcare systems, the Defense Health Agency, U.S. Coast Guard, and other federal healthcare organizations. The contract award reflects the contractor's established capability to fulfill federal procurement requirements for specialized pharmaceutical products across multiple therapeutic domains. As a child award under the larger DLA framework, this transaction demonstrates the company's role in supporting military medical readiness and veteran healthcare needs through reliable access to pharmaceutical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 11/5/25 |